News headlines about Nuvectra (NASDAQ:NVTR) have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nuvectra earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.6064399817391 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Nuvectra (NVTR) opened at $8.86 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.72 and a current ratio of 2.90. Nuvectra has a 12 month low of $4.90 and a 12 month high of $15.00.
Nuvectra (NASDAQ:NVTR) last posted its earnings results on Wednesday, November 1st. The company reported ($1.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.07. The company had revenue of $7.60 million for the quarter, compared to analysts’ expectations of $8.08 million. Nuvectra had a negative return on equity of 68.63% and a negative net margin of 204.19%. Nuvectra’s quarterly revenue was up 100.0% on a year-over-year basis. During the same period last year, the firm earned ($0.92) earnings per share. research analysts anticipate that Nuvectra will post -4.77 EPS for the current year.
Several analysts recently issued reports on NVTR shares. ValuEngine cut Nuvectra from a “hold” rating to a “sell” rating in a research note on Friday. Piper Jaffray Companies reissued a “hold” rating and issued a $12.00 target price on shares of Nuvectra in a research note on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $12.00.
COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/05/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-nuvectra-nvtr-share-price.html.
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.